Observations on screening-based research and some concerning trends in the literature

Future Medicinal Chemistry

Volumn 2, Issue 10, 2010, Pages 1529-1546

  Baell, Jonathan B ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Cancer Therapeutics CRC P/L   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,4 TETRAHYDROQUINOLINE DERIVATIVE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; BETA ALANINE; CATECHOL DERIVATIVE; CYANINE DYE; MANNICH BASE; PHENYLHYDRAZONE DERIVATIVE; PYRROLE DERIVATIVE; QUINONE DERIVATIVE; RHODANINE; SMALL MOLECULE TRANSPORT AGENT; THIOBARBITURIC ACID DERIVATIVE; THIOPHENE DERIVATIVE;

CELL PROLIFERATION; DRUG BINDING; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; DRUG SYNTHESIS; GENE EXPRESSION PROFILING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; HUMAN; MEDICAL LITERATURE; MOLECULAR DOCKING; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; ROOM TEMPERATURE; STRUCTURE ACTIVITY RELATION; TREND STUDY; TRYPANOSOMA BRUCEI;

ANIMALS; DRUG EVALUATION, PRECLINICAL; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; PHARMACEUTICAL PREPARATIONS; PROTEINS;

EID: 77958044565     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.237     Document Type: Review

References (40)

1. Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J. Med. Chem. 53(7), 2719-2740 (2010
2. McLean LR, Zhang Y, Li H. et al. Discovery of covalent inhibitors for MIF tautomerase via cocrystal structures with phantom hits from virtual screening. Bioorg. Med. Chem. Lett. 23, 6717-6720 (2009
3. Ifa DR, Rodrigues CR, de Alencastro RB, Fraga CAM, Barriero EJ. A possible molecular mechanism for the inhibition of cysteine proteases by salicylaldehyde N-acylhydrazones and related compounds. J. Mol. Struct. 505, 11-17 (2000
4. Kaumanns O, Mayr H. Electrophilicity parameters of 5-benzylidene-2,2- dimethyl[1,3]dioaxane-4,6-diones (benzylidene Meldrum's acids). J. Org. Chem. 73(7), 2738-2745 (2008
5. Regland B, Lehmann W, Abedini I. et al. Treatment of Alzheimer's disease with clioquinol. Dement. Geriatr. Cogn Disord. 12(6) 408-414 (2001
6. Ledesma GN, Sierra MG, Escandar GM. Spectroscopic and theoretical study or aromatic a-hydroxy hydrazones and their copper (II) complexes in dioxane-water mixtures. Polyhedron 17, 1517-1523 (1998
7. Ainscough EW, Brodie AM, Denny WA, Finlay GJ, Gothe SA, Ranford JD. Cytotoxicity of salicylaldehyde benzoylhydrazone analogs and their transition metal complexes: quantitative structure-activity relationships. J. Inorg. Biochem. 77, 125-133 (1999
8. Forino M, Johnson S, Wong TY et al. Efficient synthetic inhibitors of anthrax lethal factor. Proc. Natl Acad. Sci USA 102, 9499-9504 (2005
9. Powers JP, Piper DE, Li Y et al. SAR and mode of action of novel non-nucleoside inhibitors of hepatitis C NS5b RNA polymerase. J. Med. Chem. 49, 1034-1046 (2006
10. Lee G, Piper DE, Wang Z et al. Novel inhibitors of hepatitis C virus RNA-dependent RNA polymerase. J. Mol. Biol. 357, 1051-1057 (2006
11. Carter PH, Scherle PA, Muckelbauer JA et al. Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-a. Proc. Natl Acad. Sci. USA 98, 11879-11884 (2001
12. Voss ME, Carter PH, Tebben AJ et al. Both 5-arylidene-2- thioxodihydropyrimidine-4,6(1H,5H)-diones and 3-thioxo-2,3-dihydro-1H-imidazo[1, 5-a]indol-1-ones are light-dependent tumor necrosis factor-a antagonists. Bioorg. Med. Chem. Lett. 13, 533-538 (2003
13. Carlson EE, May JF, Kiessling LL. Chemical probes of UDP-galactopyranose mutase. Chem. Biol. 13, 825-837 (2006
14. van Delft MF, Wei AH, Mason KD et al. The BH3 mimetic ABT-737-targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10, 389-399 (2006
15. Degterev A, Lugovsky A, Cardone M et al. Identification of small-molecule inhibitors of the interaction between the BH3 domain and Bcl-xL. Nature Cell Biol. 3, 173-182 (2001
16. Ramesh C, Nayak TK, Burai R et al. Synthesis and characterization of iodinated tetrahydroquinolines targeting the G protein-coupled estrogen receptor GPR30. J. Med. Chem. 53(3), 1004-1014 (2010
17. Wolf MC, Freiberg AN, Zhang T et al. A broad-spectrum antiviral targeting entry of enveloped viruses. Proc. Natl Acad. Sci. USA 107(7), 3157-3162 (2010
18. Rizvi SA, Neidt EM, Cui J et al. Identification and characterization of a small molecule inhibitor of formin-mediated actin assembly. Chem. Biol. 16(11), 1158-1168 (2009
19. Bowers EM, Yan G, Mukherjee C et al. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem. Biol. 17(5), 471-482 (2010
20. Kaiser J. Industry-style screening meets academic biology. Science 321(5890), 764-766 (2008
21. Smith AJT, Zhang X, Leach AG, Houk KN. Beyond picomolar affinities: quantitative aspects of noncovalent and covalent binding of drugs to proteins. J .Med. Chem. 52(2), 225-233 (2009
22. Johnson DS, Weerapan E, Cravatt BF. Strategies for discovering and derisking covalent, irreversible enzyme inhibitors. Future Med. Chem. 2(6) 949-964 (2010
23. Aghajan M, Jonai N, Flick K et al. Chemical genetics screen for enhancers of rapamycin identifies a specific inhibitor of an SCF family E3 ubiquitin ligase. Nature Biotechnol. 28(7) 738-744 (2010
24. Rishton GM. Reactive compounds and in vitro false positives in HTS. Drug Discov. Today 2, 382-384 (1997
25. Hann M, Hudson B, Lewell X, Lifely R, Miller L, Ramsden N. Strategic pooling of compounds for high-throughput screening. J. Chem. Inf. Comput. Sci. 39, 897-902 (1999
26. Walters WP, Murcko MA. Prediction of 'drug-likeness'. Adv. Drug. Deliv. Rev. 54, 255-271 (2002
27. Huth JR, Mendoza R, Olejniczak ET et al. ALARM NMR: a rapid and robust experimental method to detect reactive false positives in biochemical screens. J. Amer. Chem. Soc. 127, 217-224 (2005
28. Thorne N, Auld DS, Inglese J. Apparent activity in high-throughput screening: origins of compound-dependent assay interference. Curr. Opin. Chem. Biol. 14, 315-324 (2010
29. Lor LL, Schneck J, McNulty DE et al. A simple assay for detection of small-molecule redox activity. J. Biomol. Screen. 12, 881-890 (2007
30. Johnston PA, Soares KM, Shinde SN et al. Development of a 384-well colorimetric assay to quantify hydrogen peroxide generated by the redox cycling of compounds in the presence of reducing agents. Ass. Drug Develop. Technol. 6, 505-518 (2008
31. Brown GR, Bamford AM, Bowyer J et al. Naphthyl ketones: a new class of janus kinase 3 inhibitors. Bioorg. Med. Chem. Lett. 10(6) 575-579 (2000
32. Arnold LA, Estebanez-Perpina E, Togashi M et al. Discovery of small molecule inhibitors of the interaction of the thyroid hormone-receptor with transcriptional coregulators. J. Biol. Chem. 280(52) 43048-43055 (2005
33. Hwang JY, Arnold LA, Zhu F et al. Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors. J. Med. Chem. 52, 3892-3901 (2009
34. Gao M, Nettles RE, Belema M et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465, 96-100 (2010
35. Frye SV. The art of the chemical probe. Nat. Chem. Biol. 6, 159-161 (2010
36. Homer RW, Swanson J, Jilek RJ, Hurst T, Clark RD. SYBYL Line notation (SLN): a single notation to represent chemical structures, queries, reactions and virtual libraries. J. Chem. Inf. Model. 48(12), 2294-2307 (2008
37. Gorsuch S, Bavetsias V, Rowlands MG et al. Synthesis of isothiazol-3-one derivatives as inhibitors of histone acetyltransferases (HATs). Bioorg. Med. Chem. 17(2), 467-474 (2009
38. Martin DC, Jones DC, Fairlamb AH, Clardy J. High-throughput screening affords novel and selective trypanothione reductase inhibitors with anti-trypanosomal activity. Bioorg. Med. Chem. Lett. 17(5) 1280-1283 (2007
39. Collaborative drug discovery blog. http://collaborativedrug.com/blog/ blog/2010/03/08/guest-blog-dr-jonathan-baell
40. Christopher A Lipinski Presesentation. http://collaborativedrug.com/blog/ files/2009/10/Lipinski-CDD- usergroup100109-with-Kellan-alerts-slide.pdf